ERBB2 and gastric cancer: While trastuzumab has demonstrated improved overall survival (OS) and progression‐free survival (PFS) in HER2‐positive advanced GC [46], resistance to trastuzumab remains a significant concern for the majority of patients [10, 47, 48].